Kardigan (KARD) Stock Overview

Operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. More details

KARD fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Analysts in good agreement that stock price will rise by 106.4%

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

KARD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW481,888 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

481,888 investors already sharing narratives

View all narratives

Kardigan, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Kardigan
Historical stock prices
Current Share Price	US$20.50
52 Week High	US$27.00
52 Week Low	US$16.25
Beta	0
1 Month Change	-16.79%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-6.82%

Recent updates

Shareholder Returns

	KARD	US Pharmaceuticals	US Market
7D	2.7%	3.2%	2.7%
1Y	n/a	57.6%	20.9%

Return vs Industry: Insufficient data to determine how KARD performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how KARD performed against the US Market.

Price Volatility

Is KARD's price volatile compared to industry and market?
KARD volatility
KARD Average Weekly Movement	9.6%
Pharmaceuticals Industry Average Movement	9.3%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: KARD has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine KARD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2023	241	Tassos Anastasios Gianakakos	www.kardigan.bio

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking.

Kardigan, Inc. Fundamentals Summary

How do Kardigan's earnings and revenue compare to its market cap?
KARD fundamental statistics
Market cap	US$1.83b
Earnings (TTM)	-US$229.99m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-8.0x

P/E Ratio

Is KARD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KARD income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$229.99m
Earnings	-US$229.99m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-2.57
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did KARD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/10 19:15
End of Day Share Price	2026/08/07 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kardigan, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yuchen Ding	Jefferies LLC
Anupam Rama	J.P. Morgan
Roanna Clarissa Ruiz	Leerink Partners LLC

Kardigan, Inc.NasdaqGM:KARD Stock Report